Cargando…
Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
PURPOSE: Several tau PET tracers have been developed, but it remains unclear whether they bind to the same molecular target on the heterogeneous tau pathology. In this study we evaluated the binding of two chemically different tau-specific PET tracers ((11)C-THK5351 and (11)C-PBB3) in a head-to-head...
Autores principales: | Chiotis, Konstantinos, Stenkrona, Per, Almkvist, Ove, Stepanov, Vladimir, Ferreira, Daniel, Arakawa, Ryosuke, Takano, Akihiro, Westman, Eric, Varrone, Andrea, Okamura, Nobuyuki, Shimada, Hitoshi, Higuchi, Makoto, Halldin, Christer, Nordberg, Agneta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061462/ https://www.ncbi.nlm.nih.gov/pubmed/29752516 http://dx.doi.org/10.1007/s00259-018-4012-5 |
Ejemplares similares
-
Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017) -
Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016) -
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016) -
(11)C-Pittsburgh compound B and (18)F-THK 5351 positron emission tomography brain imaging in cognitively normal individuals
por: Chotipanich, Chanisa, et al.
Publicado: (2020) -
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)